Rebirthel Co., Ltd. concluded an agreement to collaborate with Fujita Health University to develop a new therapy for novel coronavirus infection and entered into the contract. Killer T cells which are regenerated from iPS cells will be used. For details, please refer to the attached press release.
NEWS 2020.10.14 Rebirthel concluded the research collaboration agreement with Fujita Health University. – Joint development of the therapy for the novel coronavirus infection using universal killer T cells –